New drug combo aims to shrink lung tumors before surgery
NCT ID NCT07538193
First seen Apr 22, 2026 · Last updated Jun 09, 2026 · Updated 9 times
Summary
This study tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) given with chemotherapy before surgery for people with a specific type of advanced lung cancer (stage III-N2b). The goal is to see if this treatment can shrink or eliminate the tumor before it is removed. About 28 adults will take part in this early-phase study across several hospitals in China.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospitial
Xi'an, Shannxi, China
Conditions
Explore the condition pages connected to this study.